Filariae are parasitic nematodes that are transmitted to their definitive host as third-stage larvae by arthropod vectors like mosquitoes. Filariae cause diseases including: lymphatic filariasis with distressing and disturbing symptoms like elephantiasis; and river blindness. Filarial diseases affect millions of people in 73 countries throughout the topics and sub-tropics. The drugs available for mass drug administration, (ivermectin, albendazole and diethylcarbamazine), are ineffective against adult filariae (macrofilariae) at the registered dosing regimen; this generates a real and urgent need to identify effective macrofilaricides. Emodepside, a veterinary anthelmintic registered for treatment of nematode infections in cats and dogs, is reported to have macrofilaricidal effects. Here, we explore the mode of action of emodepside using adult Brugia malayi, one of the species that causes lymphatic filariasis. Whole-parasite motility measurement with Worminator and patch-clamp of single muscle cells show that emodepside potently inhibits motility by activating voltage-gated potassium channels and that the male is more sensitive than the female. RNAi knock down suggests that emodepside targets SLO-1 K channels. We expressed slo-1 isoforms, with alternatively spliced exons at the RCK1 (Regulator of Conductance of Potassium) domain, heterologously in Xenopus laevis oocytes. We discovered that the slo-1f isoform, found in muscles of males, is more sensitive to emodepside than the slo-1a isoform found in muscles of females; and selective RNAi of the slo-1a isoform in female worms increased emodepside potency. In Onchocerca volvulus, that causes river blindness, we found two isoforms in adult females with homology to Bma-SLO-1A and Bma-SLO-1F at the RCK1 domain. In silico modeling identified an emodepside binding pocket in the same RCK1 region of different species of filaria that is affected by these splice variations. Our observations show that emodepside has potent macrofilaricidal effects and alternative splicing in the RCK1 binding pocket affects potency. Therefore, the evaluation of potential sex-dependent effects of an anthelmintic compound is of importance to prevent any under-dosing of one or the other gender of nematodes once given to patients.
Filariae are parasitic nematodes that reside in the definitive host which are always mammals. The adult filariae are referred to as macrofilariae. The adult females release microscopic juveniles, microfilariae, which are then ingested during a blood meal by the arthropod vectors. These microfilariae develop in the arthropod host to the infectious third-stage larvae which can then be transmitted to the mammalian host during a subsequent blood meal. The filaroide species that are responsible for most of the morbidity are Wuchereria bancrofti, Brugia malayi and Brugia timori that cause lymphatic filariasis (including elephantiasis), and Onchocerca volvulus that causes river blindness (onchocerciasis) [1]. These diseases occur mostly in sub-Saharan Africa and Southeast Asia and affect 168 million people. Some 120 million people are infected with lymphatic filariases and around 20 million people are affected by onchocerciasis. The diseases are not usually fatal, but they produce distressing symptoms including, swollen limbs, blindness, reduced work productivity, social rejection and suppression of immune responses to diseases like, malaria and tuberculosis. For over 25 years now, the strategy for controlling filarial diseases has relied on Mass Drug Administration (MDA) programs directed by the World Health Organization using donated drugs to reduce the transmission and morbidity of these filarial diseases. The MDA programs have been successful in several countries, but the filarial diseases still persist, and have not been eliminated [2]. The existing drugs that are now available for MDA (albendazole and ivermectin or diethylcarbamazine for lymphatic filariasis, and ivermectin alone for onchocerciasis are effective against the early larval stages of the parasites (microfilariae), but they do not kill the adults (macrofilariae) efficiently. These repeated annual treatments in MDA programs were modelled to take more than 6–8 years to control lymphatic filariasis, and >15 years to eliminate onchocerciasis because the adults persist and continue to release microfilaria between drug treatments and to spread infection. To accelerate the control measures, there is a real need to identify effective macrofilaricides. The Drugs for Neglected Diseases initiative (DNDi) development program has focused on macrofilaricide drug candidates from repurposing libraries and have included drugs that have been registered for animal health [3]. Emodepside is a veterinary drug that has effects on adult filarial nematodes [4] and has completed first-in-human safety and tolerability studies in healthy volunteers with the purpose of being developed for the treatment of onchocerciasis [5]. Emodepside is a semisynthetic derivative of the cyclooctadepsipeptide PF1022A that was isolated from Rosellinia spp. , a fungus that grows on Camellia japonica [6]. Emodepside is effective for treating animal nematode parasites that are resistant to other common anthelmintics [7]. It inhibits motility in nematodes, via an effect that may be mediated through GABAA receptors [8,9], lathrophilin receptors [10,11] or SLO-1 K channels [12–15]. The general consensus is that SLO-1 is the main target of emodepside in nematodes [16]. Detailed modes of action studies in filarial nematodes are required to advance the evaluation of emodepside as a macrofilaricide. The effects of emodepside against filariae are dose- and species-dependent. In studies using Litomosoides carinii (syn. L. sigmodontis), Acanthocheinlonema viteae, Brugia malayi, Brugia pahangi, Onchocerca gutturosa and Onchocerca lienalis, the adults of Brugia spp. emerged as the dose-limiting stage where emodepside was least potent [17,18]. Here we study the mode of action of, and sensitivity to, emodepside using the dose-limiting filarial nematode, B. malayi. RNAi knock down experiments demonstrated that emodepside targets the SLO-1 K channels. We expressed slo-1 isoforms with alternatively spliced exons in the RCK1 domain heterologously in Xenopus laevis oocytes and observed that the slo-1f splice variant, found in muscles of males, is more sensitive to emodepside than the slo-1a splice variant found in muscle of females. We also demonstrate selectively knocking down the slo-1a splice variant in female B. malayi increases emodepside efficacy, signifying a dominant suppressor role for SLO-1A. Further, we show that similar alternatively spliced isoforms are expressed in O. volvulus. In silico modeling identified a putative emodepside binding pocket in the same RCK1 region of different species of filariae that is affected by these splice variations. Our observations show the potent macrofilaricidal effects of emodepside are influenced by sex-linked splice variants in the RCK1 binding pocket of SLO-1. The sex of the filarial target is therefore an important therapeutic variable to consider when evaluating a dose-regimen for treatments during clinical trials [5].
We selected B. malayi, Fig 1A, a ‘dose-limiting species’, to pursue the investigation of the effects of emodepside. Initially, we used motility assays to determine emodepside IC50 values from concentration-response relationships of adult males and females. Emodepside causes flaccid paralysis of the adult worm. Both the male and female worms show reduced motility as early as 10 minutes exposure at the highest concentration tested, 10μM. Fig 1B & 1C shows that the immobilizing effects of emodepside were concentration-, time- and sex-dependent. When we plotted the emodepside- concentration motility-response at 60 minutes, the male is 4. 5x more sensitive to emodepside than the female, Fig 1D & 1E: the male IC50 was 176±33 nM and the female IC50 was 801±126 nM (p<0. 001; 2-way ANOVA; n = 12). The gender-difference in sensitivity is therapeutically relevant if the female worm remains after treatment to release microfilariae allowing continued transmission of the infection. One possible explanation for the gender-linked sensitivity was the bigger size of the female worms (length 43 to 55 mm) compared to the males worms (length 13 to 23 mm), limiting the bioavailability of emodepside within the female worm. To investigate the direct effect of emodepside on muscle cells we used dissected preparations [19,20] from female and male worms and recorded the responses in exposed muscle cells using patch-clamp. When we used a voltage-step protocol to activate voltage-sensitive potassium currents in muscle cells, we found that these currents increased in the presence of emodepside. S1A & S1B Fig shows representative currents activated by depolarizing steps from a holding potential of -40mV in female worms. The major effect of emodepside on the potassium current activation curve was to increase Gmax from 14±2 pS to 23±1 pS (p<0. 001; Student’s t-test; n = 5), suggesting an increase in the number of channels opening and/or the open probability of the channels. There was only a small increase in the voltage sensitivity with the V50 changing from 8±1 mV to -2±1 mV (p<0. 001; n = 5; paired t-test; S1C Fig), showing that a change in sensitivity of the channels to depolarization is not a major mechanism of action of emodepside. To compare the effects of emodepside on male and female muscle cells, we measured the increases in the outward standing currents at a potential near the resting membrane potential, -40mV, Fig 2A & 2B. The males were more sensitive to emodepside than the females. The IC50 of male muscle cells was significantly less (~2. 5x) than that of female muscle cells: 294±11nM in males (n = 5) and 717±12nM (n = 5) in females (p<0. 001; 2-way ANOVA). It is pointed out however that the Imaxs of female muscle cells were bigger than that of male muscle cells, which may be explained by the larger size of the female muscle and the activation of more SLO-1 channels. These IC50s and the differences between males and females are similar to the IC50s seen for the whole worm motility experiments (Fig 1C & 1D). The patch-clamp experiments showed that: a) the size of the worm and the cuticle barrier had little effect on emodepside potency; b) emodepside is more potent on male worm muscle cells than on female worm muscle cells; and c) emodepside affects B. malayi muscle by activating standing outward (hyperpolarizing) currents. The parasite genome has several potassium channels and it is likely that more than one potassium channel type is expressed in somatic muscles. We used a selective SLO-1 K channel inhibitor, iberiotoxin [21], a toxin from the scorpion Buthus tamulus that binds selectively to the external surface of SLO-1 K channels. We found that iberiotoxin by itself had little effect on the standing current, S2A Fig, but significantly (p<0. 005; Student’s paired t-test; n = 7) inhibited the emodepside-activated outward current, S2A & S2B Fig. This inhibition supports the hypothesis that the mode of action of emodepside in filariae is to activate SLO-1 K channels. We knocked down the slo-1 transcript in adult female B. malayi to see if we could produce a SLO-1 loss of function phenotype that shows resistance to emodepside. We used slo-1 targeting dsRNA and were able to knock down its expression by 91±2% after 3 days (Fig 3A), which was significant (p<0. 005; Student’s t-test; n = 6) when compared to the control worms treated with lacZ dsRNA that showed a 22±12% decrease in the slo-1 transcript. The dsRNA treatments produced little change in motility over a period of 72 hours (Fig 3B). When we treated the slo-1 knock down worms with 300nM emodepside and measured their motility over a period of two hours, we found that worms treated with slo-1 specific dsRNA were resistant (two-way ANOVA; p<0. 001) to emodepside as compared to lacZ dsRNA treated control worms (Fig 3C). These results show that emodepside requires SLO-1 K channels to paralyze adult B. malayi. SLO-1 channels in filaria are highly conserved, but alternative splicing can produce channel isoforms [22] which could alter their pharmacology. In the B. malayi genome (parasite. wormbase. org) there are 5 predicted slo-1 isoforms, a, b, c e and f, S3A Fig. Splice variants a and f are full length, b and c lack the first exon, while e is a truncated version. Between a, b, c and f, the splice sites are predicted to be in exon 2 and in exon 14 of the slo-1 gene. To identify the splice variants that are present in B. malayi, we made the primers BSloR1 and BSloR2 to cover and amplify this region from B. malayi cDNA. We amplified 5’ end of the slo-1 gene using 5’ splice leader 2 primer and were able to amplify a single band confirming the expression of just two splice variants, slo-1a & slo-1f (S3B and S3C Fig). We have shown the greater potency of emodepside on male worms compared to female B. malayi worms (Figs 1 and 2). We hypothesized that this difference may arise from differences in the expression of slo-1 splice variants between the sexes. To test this, we used a NcoI restriction site to cut slo-1a specifically at exon 14; we amplified full-length slo-1 transcript from cDNA collected via the patch-pipettes from single muscle cells of both male and female adult worms and cut both the amplicons using the restriction enzyme NcoI. We found clear differences in the expression of the slo-1 splice variants between the sexes of adult B. malayi (S3C Fig): splice variants slo-1a and slo-1f were both expressed in female worms, but only slo-1f was expressed in male worms. We cloned both Bma-slo-1a and Bma-slo-1f into an expression vector (pTB207) to express the channels in Xenopus laevis oocytes. We recorded evoked currents in response to emodepside using two-electrode voltage-clamp with oocytes held at +20mV. Control experiments on water-injected oocytes produced no response (Fig 4A). Robust concentration-dependent current responses that had peak currents of over 400nA were seen with oocytes injected with slo-1f (Fig 4B). When we expressed slo-1a, or slo-1a with slo-1f (Fig 4C & 4D), we found much smaller, but still detectable currents. The EC50 for SLO-1F was 5±1μM (n = 7), which was significantly (p<0. 001; Student’s t-test) lower than that of the SLO-1A and the SLO-1F + SLO-1A combination (EC50 > 30μM; n = 7) for both, Fig 4E. These observations show that emodepside displays different potencies on different splice variants of Bma-slo-1. We point out that the emodepside EC50s from the oocyte experiments are higher than those obtained from the whole worm motility and muscle patch-clamp experiments, which might be explained by the absence of interacting proteins like ISLO-1 (Interactor with SLO-1), BKIP-1 (BK channel interacting protein) [16,23]. We demonstrated earlier that knock down of slo-1 causes a resistance to emodepside phenotype (Fig 3C) due to the loss of both the slo-1a and slo-1f splice variants. As shown in S3A Fig, the difference in the homology between SLO-1A and SLO-1F is in a single alternatively spliced exon. Of the 37 amino acids in the region of exon-14,11 amino acids are different because of the splice variation. To further test the hypothesis that expression of slo-1a splice variant reduces the emodepside potency, the region of exon-14 of slo-1a was synthesized as single strands, annealed and dsRNA was synthesized. We then selectively knocked down slo-1a in female B. malayi. Female worms treated with off-target lacZ and male worms treated with slo-1a specific dsRNA were used as controls. Worms were soaked in the dsRNA for 72 hours and were then treated with increasing doses of emodepside. Emodepside was then more potent (IC50: 242 ± 75nM) in female worms treated with slo-1a dsRNA (Fig 5A & 5B): the IC50 was 3 times lower than in control female worms (IC50: 617 ± 207nM) treated with lacZ dsRNA (2-way ANOVA; p<0. 05; n = 8). We point out that male worms treated with slo-1a dsRNA showed little change in their IC50 (181 ± 43nM, Fig 1E vs 182 ± 42nM, Fig 5A & 5B). We obtained cDNA from both male and female worms and used restriction enzymes PvuII to selectively cut slo-1f, and NcoI to selectively cut slo-1a. We performed qPCR on the cleaved DNA and confirmed greater than 80% knockdown (P<0. 01, Student’s t-test, n = 5) of slo-1a transcript in female worms (S4A Fig) but no significant change of the slo-1f in the female or male worms (S4A & S4B Fig). We point out that PvuII and NcoI does not cleave the region of gapdh we amplified for quantification. We have shown that the potency of emodepside differs with the splice variants of slo-1 in B. malayi. The divergence in the sequence between SLO-1A and SLO-1F is found in the cytoplasmic RCK1 domain, suggesting that this region is involved in emodepside binding. We performed in-silico binding experiments and tested the docking of the three most thermodynamically stable structures of emodepside to modeled structures of the cytoplasmic domain of SLO-1F and SLO-1A isoforms of B. malayi. We found (Figs 6 & 7A–7E) that emodepside binds most favorably within the same pocket of Bma-SLO-1, which was formed by five putative binding loops (loop A: amino acids 389–400 defined using Bma-SLO-1F; loop B: 442–449; loop C: 562–567; loop D: 622–638; and loop E: 965–973, Figs 6 and 7E and Table 1). Loops A-D are present in the RCK1 region. The amino acid differences in loop C (see E566D and S567T; red arrows, Fig 7E) due to alternative splicing in exon 14 changed the binding energy of SLO-1F from -6. 23 kCal/mol to -4. 45 kCal/mol of SLO-1A. Loop E is present in the RCK2 region near the calcium bowl (amino acids 930–938) region. Fig 7E shows with vertical arrows amino acids on these loops that directly interacts with emodepside. We investigated the SLO-1 RCK1 region of other filaria species to explore the binding of emodepside. In O. volvulus, the filaria that causes river blindness, we made similar observations. O. volvulus has 5 predicted slo-1 splice variants (Wormbase, OVOC4127a –d & f; e is a truncated form with the RCK domains absent). When the cDNA from female O. volvulus was amplified between exons 9 and 19 of slo-1 only two splice variants were expressed: Ovo-SLO-1A and Ovo-SLO-1D (S5 Fig). In silico experiments revealed that emodepside binds most favorably to the same regions, loops A-E in O. volvulus as in B. malayi (S6 Fig). The emodepside binding energies being -5. 08 kCal/mol to Ovo-SLO-1A and -5. 60 kCal/mol to Ovo-SLO-1D. Interestingly, both of these energies are higher than the emodepside binding energy for the limiting SLO-1A splice variant of B. malayi and imply a greater potency of emodepside in O. volvulus. We also modelled the in-silico binding of emodepside to the SLO-1 Ks of the filaria, Dirofilaria immitis and Litomosoides sigmodontis using the available Parasite Wormbase (parasite. wormbase. org) sequences, Fig 6, although it lacks information about splice variants. Again, we found that emodepside binds most favorably to the same putative pockets defined by the same A-E loops (Figs 6 & S6).
DNDi in collaboration with Bayer AG have pursued the development of emodepside, originally a veterinary anthelmintic, with the aim of it being the first registered oral macrofilaricide treatment for a filarial disease, onchocerciasis, with DNDi planning to run a Phase II “proof-of-concept” clinical trial in sub-Saharan Africa investigating the safety and efficacy of the drug. It has been shown to be effective, albeit with varying potency, against other filarial nematode species in in vitro and in vivo models using rodents [4,17,18]. Here we show that emodepside has concentration-dependent activity even against the dose-limiting filarial species, Brugia malayi. An oral dose of 1. 9mg/Kg emodepside produces a maximum plasma concentration of 150μg/L or 125nM in dogs with emodepside being distributed to all organs and the highest concentrations being found in the fat [24]. The IC50 for the adult cattle filaria, O. gutturosa in vitro, is estimated to be <1nM [4]. If 125nM concentrations of emodepside are achieved in humans following treatment, and O. volvulus is as sensitive to emodepside as O. gutturosa, emodepside is anticipated to be effective against onchocerciasis. The effectiveness and safety profile of emodepside against B. malayi has yet to be determined in humans. Our results predict that higher plasma concentrations of emodepside would be required against B. malayi. We find that emodepside was more potent on Bma-SLO-1F than Bma-SLO-1A. We observe that there is alternative splicing in the RCK1 region in B. malayi (slo-1a and slo-1f) and that there are differences in the RCK1 amino acid sequences between the other filarial species as well. In the full-length SLO-1 splice variants of B. malayi and O. volvulus, we find the same alternatively spliced regions between exons 13–20 which encode the RCK1 region. We do not comment more specifically on alternatively spliced slo-1 transcripts of L. sigmodontis due to the lack of sequence information in the database. Although there is a report of splice variants being expressed in D. immitis with alternatively spliced exons in the RCK1 region, very similar to B. malayi [22], we do not have the full-length sequences from the Wormbase Parasite database for D. immitis to use in our study. Nonetheless, we still find less homology between different filarial species in the RCK1 region compared to RCK2 (Fig 6). Given these differences in the RCK 1 regions, the reduced potency of emodepside in B. malayi and sensitivity of Onchocerca species, we looked in-silico at the RCK1 region for emodepside binding sites (Fig 6). We found that in all species of filaria examined that emodepside binds most favorably in the same pocket bound by five separate loops, A-E. Loops A-D are present in the RCK1 region (S6 Fig). Loop E is present in the RCK2 region adjacent to the Calcium Bowl. The in silico observations showing emodepside binding to the RCK1 region of O. volvulus further advances our knowledge of its effectiveness as a macrofilaricide for the treatment of river blindness. Observations on a number of C. elegans SLO-1 mutants have also noted that amino-acid changes in the RCK1 region reduces emodepside potency, supporting the presence of an emodepside binding pocket in this region [15,25]. Our observations do not rule out additional binding of emodepside to transmembrane regions of the channel in the lipid phase of the membrane; but we observed only a small change in the voltage-sensitivity of the channel that would, if large, indicate an effect mediated via the voltage-sensing domain in the membrane [26,27]. We have observed that emodepside is more potent on male B. malayi than females and therefore the gender of nematodes has an effect as a variable on the outcome of emodepside treatment. Insufficient concentrations of emodepside would leave the female worms surviving treatment to continue their life cycle and the diseases. The National Institutes of Health (NIH) expects that scientists test for the possible role of gender as a biological variable in vertebrate animals and humans (Notice Number NOT-OD-15-102) but does not require reporting of gender as a variable on invertebrates, here parasitic nematodes. This study shows that gender is a significant factor for the effect of emodepside. Significant gender-dependent differences in the metabolism of anthelmintics has been observed for Haemonchus contortus [28] with females metabolizing benzimidazole anthelmintics more extensively than males and resistance of H. contortus females showing greater sensitivity to ivermectin than males [29] but gender-linked effects are not found routinely [30]. We advocate that gender, as a variable for parasitic nematodes should be investigated as early as possible because of potential therapeutic consequences.
Our observations show that emodepside has potent, gender-dependent, inhibitory effects on the motility of B. malayi that is mediated by activation of SLO-1 potassium channels in adult Brugia malayi filaria. Importantly, splice variants and mutations in the RCK regions of the binding pocket for emodepside can alter the potency of emodepside. As the potency of an anthelmintic drug can be different against one life-cycle stage than another, in this particular case female less than that on the male macrofilariae, it is of major importance to define the dose-regimen based all stages that need to be eliminated with the treatment.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
B. malayi adult worms were obtained from the NIH/NIAID Filariasis Research Reagent Resource Center (FR3; College of Veterinary Medicine, University of Georgia, Athens, GA, USA). Adult worms were maintained in non-phenol red Roswell Park Memorial Institute (RPMI) 1640 media (Life Technologies, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Fisher Scientific, USA) and 1% penicillin-streptomycin (Life Technologies, USA). The worms were stored individually in 24 well microtiter plates containing 2 mL RPMI -1640 media containing L-glutamine and placed in an incubator at 37°C supplemented with 5% CO2. Movement of worms was analyzed in a 24-well microtiter plate using the Worminator system as explained by [31]. The output of the Worminator, Mean Movement Units (MMU), measures the pixel displacement of each worm over time and decreases to zero for stationary worms. Each worm was placed in a single well of the microtiter plate containing 1 mL of RPMI media containing L-glutamine. For emodepside concentration-response analysis, once the drugs were added the motility of the worms was recorded 0,10,20,30,40,60,90 and 120 minutes post treatment. Emodepside was dissolved in DMSO (final concentration of 0. 1% (v/v) ) and the same concentration of DMSO was used in control worms. For dsRNA experiments, either 30 μg/mL of Bma-slo-1, LacZ dsRNA or DNA/RNase free water were used. The movement of worms was recorded at 0,24,48,72 and 96 hours post dsRNA treatment using the WormAssay v1. 4 software. Motility of control worms was also recorded before the application of dsRNA. The worms were treated with emodepside after 96 hours of RNAi. The motility of the worms was recorded at 0,15,30,45,60,90 and 120 minutes post treatment. % motility was calculated as a percentage ratio of motility of worms after treatment at each time point over motility of naïve worms. Once all the worms were dissected, the recordings were performed at room temperature. The muscle cells and the hypodermis were exposed upon dissection by modifying the methods used for C. elegans [32,33]. Sections of about 5mm were cut from the anterior region of the worm and placed in the recording chamber with bath solution (23 mM NaCl, 110 mM Sodium acetate, 5 mM KCl, 6 mM CaCl2,4 mM MgCl2,5 mM HEPES, 10 mM d-glucose, and 11 mM sucrose, pH adjusted to 7. 2 with NaOH, ~320 mosmol). The base of the chamber was a 24 × 50 mm cover slip coated with a thin layer of Sylgard. The worm section was then glued along one side using Glushield cyanoacrylate glue (Glustitch Inc, Canada) thereby immobilizing it and then cut open longitudinally using a tungsten needle. The resulting ‘muscle flap’ was glued along the cut edge and the reproductive and the gut tissue were removed using fine forceps. The dissection was viewed under DIC optics (400X) using an inverted light microscope (TE2000U, Nikon, USA). Muscle flaps were incubated in 1 mg/ml collagenase (Type 1A) in bath solution for 15-120s and washed 10 times prior to recording. The patch-clamp technique was used to record whole-cell currents from the muscle flaps as explained in [34]. Patch pipettes were pulled from capillary glass (G85150T; Warner Instruments Inc. , Hamden, CT, USA), fire polished and then filled with pipette solution (120 mM KCl, 20 mM KOH, 4 mM MgCl2,5 mM TRIS, 0. 25 mM CaCl2,4 mM NaATP, 5 mM EGTA and 36 mM sucrose (pH 7. 2 with KOH), ~315–330 mosmol). Pipettes with resistances of 3–5 MΩ were used. A 1 cm region near the tip of the electrode was covered with Sylgard to reduce background noise and improve frequency responses. Giga ohm seal was formed before breaking the membrane with suction. The preparation was continuously perfused in bath solution at 2 ml/min. The current signal was amplified by an Axopatch 200B amplifier (Molecular Devices, CA, USA) filtered at 2 kHz (three-pole Bessel filter), and sampled at 25 kHz, digitized with a Digidata 1440 (Molecular Devices, CA, USA). Worms were snap frozen and crushed into fine powder in a 1. 5 mL micro-centrifuge tube using Kimble Kontes Pellet Pestle (Fisher Scientific, USA). Total RNA was extracted using TRIzol Reagent (Life Technologies, USA) according to the manufacturer’s instructions. About 1μg of total RNA was used to synthesize cDNA using SuperScript VILO Master Mix (Life Technologies, USA). Samples were either used to amplify DNA using PCR or stored at -20°C for later use. dsRNA was synthesized as explained in [20,35]. Target and non-target T7 promoter labelled primers were amplified using the primers SSK 34F, SSK 34R, SSK 34Ft7 and SSK 34Rt7 for the target Bma-slo-1, LacZF, LacZR, LacZFt7 and LacZRt7 for the non-target LacZ. The sequences of these primers are shown in Table 2. Amplification was done using Techne PRIMEG (Bibby Scientific Limited, UK) with cycling conditions -95°C x 5 min, 35 x (95°C x 30s, 55°C x 30s, 72°C x 1 min), 72°C x 10min from sequence verified cDNA templates. dsRNA was synthesized T7 RiboMAX Express RNAi kit (Promega, USA) according to the manufacturer’s instructions. Concentration and purity of dsRNA were assessed using a spectrophotometer. Adult B. malayi were soaked in 30 μg/mL of dsRNA for 4 days. Worms were maintained in RPMI media as explained before. A part of the worm was cut for electrophysiology recordings and the rest were snap frozen in liquid nitrogen and stored at -80°C for transcript analysis. cDNA from dsRNA treated worms were amplified using target (Bma slo-1) and reference gene (Bma gapdh) primers–SSK 34F, SSK 34R, SSK 5F and SSK 5R (Table 2). These genes were amplified in triplicate by quantitative real-time PCR (qPCR) using the CFX96 Touch Real-Time PCR Detection System and SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, USA). Cycling conditions used: 95°C x 10min, 40 x (95°C x 10s, 55°C x 30s). PCR efficiencies were calculated using the CFX96 Software Suite (Bio-Rad, USA). Relative quantification of target gene knock down was estimated by the ΔΔCt method [36]. Defolliculated Xenopus laevis oocytes were purchased from Ecocyte Bioscience (Austin, TX, USA). Full length slo-1 was amplified using Platinum SuperFi Polymerase Master Mix (ThermoFisher, USA) in a thermocycler. Primers (SSK 48F and SSK 48R) were made with sequences flanking the expression vector pTB207 including the restriction site (BamHI) between which slo-1 was inserted (Table 1). The amplicon was then purified using NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel) and cloned into pTB207 by using Infusion HD Cloning Kit (Takara Bio USA, Inc.) using the manufacturer’s guidelines. Upon cloning, the plasmids were sequence verified, linearized by MscI and purified for in vitro transcription using the mMessage mMachine T7 Transcription Kit (Ambion, USA). The cRNA was precipitated with lithium chloride, re-suspended in nuclease free water, and stored at -80°C. The cRNA was then injected into Xenopus laevis oocytes kept at 20°C for ~3 hours prior to injections in incubation solution (100 mM NaCl, 2 mM KCl, 1. 8 mM CaCl2. 2H20,1 mM MgCl2. 6H20,5 mM HEPES, 2. 5 mM Na pyruvate, 100 U/mL penicillin and 100 μg/mL streptomycin, pH 7. 5). 15ng of slo-1 cRNA was injected into the animal pole of the oocytes using a nanoject II microinjector (Drummond Scientific, PA, USA). The injected oocytes were transferred into 96-well culture plates containing 200μL incubation solution per well; each well contained one oocyte. Oocytes were incubated at 20°C for 5–6 days to allow for receptor expression, incubation solution was changed daily. Oocytes with membrane potentials less than -15 mV were excluded from recording. Oocyte recordings that failed (shown by a change in the holding current following wash) before the complete series of drug applications were excluded from the analysis. Two-electrode voltage-clamp electrophysiology was used to record currents produced by activation of the expressed Bma-SLO-1 channels. Recordings from water injected oocytes served as control experiments. Recordings were made using an Axoclamp 2B amplifier (Warner Instruments, USA) with the oocytes voltage-clamped at +20 mV, and data acquired on a computer with Clampex 10. 3 (Molecular Devices, CA, USA). The microelectrodes used to impale the oocytes were pulled using a Flaming/Brown horizontal electrode puller (Model P-97, Sutter Instruments, USA) set to pull micropipettes that when filled with 3 M KCl had a resistance of 20–30 MΩ. The micropipettes tips were carefully broken with a piece of tissue paper in order to achieve a resistance of 2–5 MΩ in recording solution (100 mM NaCl, 2. 5 mM KCl, 1 mM CaCl2. 2H2O and 5 mM HEPES, pH 7. 3). The low resistance pipettes allowed large currents to be passed to maintain adequate voltage-clamp. Emodepside used in this study was obtained from Bayer Animal Health. Potassium channel inhibitor iberiotoxin from Sigma Aldrich (St. Louis, MO, USA). The drugs were solubilized in DMSO and diluted in recording solution. The molecular structure of emodepside was obtained from DrugBank (DB). Docking studies were performed using AutoDock (The Scripps Research Institute) as explained in [37]. AutoDock does not consider single bonds in non-aromatic cycles as rotatable bonds. To add more flexibility to the structure of emodepside, we used Marvin Sketch and the minimization under MMFF94 force field provided in the Marvin Suite (www. chemaxon. com/products/marvin/marvinsketch/). The ten least energy conformers were evaluated using pairwise root mean square deviations (RMSD) for atomic positions using PyMOL. Conformers 1,2 and 4 were used for further docking analysis. Molecular docking experiments were performed using AutoDock 4. 2. 6. Structures of filarial SLO-1 were modelled using Swiss Model (https: //swissmodel. expasy. org). The structures were kept rigid and only the cytosolic region of monomeric SLO-1 was used for docking. Due to the absence of literature about the exact location of the binding site, the entire cytosolic region was taken into account for the computation. The grid box drawn using AutoGrid 4 included 126,126 and 126 points in the x, y and z directions with a grid spacing of 0. 586Å. For each ligand conformer, 25 independent computations were performed using Lamarckian genetic algorithm. All other parameters were set to default value. The pose with the least binding energy for each filarial species was compared and the interacting amino acids were mapped in AutoDock. Whole-cell patch clamp data were analyzed with Clampfit 9. 2 (Molecular Devices, CA, USA) and GraphPad Prism 5. 0 software. The peak current responses from whole-cell recordings were used for analysis. For two-electrode voltage clamp experiments, the response to 30 μM emodepside was used to normalize the concentration–response relationship. For whole worm concentration–response relationships, motility/minute was plotted against log concentration. Emodepside concentrations were log10 transformed before analysis. The log agonist vs. response equation (variable slope) was used to generate concentration response curves to calculate EC50 values. The responses were plotted as the mean ± Standard Error of Mean (SEM). Statistical analyses were performed on groups of values by using ANOVA to determine whether the group means were dissimilar; Bonferroni post-hoc tests were used for multiple comparison tests to determine whether there were significant differences between groups. Student’s t-tests were used for comparing a simple control with a test study effect.
Emodepside is an anthelmintic drug that is used for treatment of nematode infections in cats and dogs. A potassium channel, SLO-1, has been implicated as a target for emodepside in the nematode model Caenorhabditis elegans. The anthelmintic effects of emodepside has been demonstrated against filariae, but its molecular mode of action requires further elucidation. Here, we show that emodepside activates SLO-1 channels in the human filaria, Brugia malayi, one of the causative agents of lymphatic filariasis. Emodepside is more potent on male than on the female B. malayi. Worms where slo-1 was knocked down were less susceptible to emodepside. Alternative splicing of the slo-1 gene in the region encoding the RCK1 domain, results in the expression of SLO-1F and SLO-1A in female worms and SLO-1F alone in male worms. SLO-1F expressed in Xenopus laevis oocytes was more sensitive to emodepside than SLO-1A or a combination of SLO-1A and SLO-1F. Selective knockdown of slo-1a in female worms increased their emodepside sensitivity, so their sensitivity resembled male worms. Emodepside binds to the RCK1 region of SLO-1 in in-silico protein interaction studies of the SLO-1 sequences of different filariod species. This is the first report demonstrating a gender-specific effect of emodepside correlating directly to the expression of alternatively spliced isoforms of SLO-1. This study emphasizes that the gender-dependent effects should always be considered when evaluating the efficacy profile of an anthelmintic drug candidate.
invertebrates
medicine and health sciences
onchocerca volvulus
muscle tissue
helminths
tropical diseases
vertebrates
parasitic diseases
animals
onchocerca
xenopus
nematode infections
animal models
alternative splicing
model organisms
brugia
amphibians
experimental organism systems
neglected tropical diseases
onchocerciasis
veterinary science
research and analysis methods
veterinary diseases
animal studies
animal cells
gene expression
biological tissue
muscle cells
xenopus oocytes
biochemistry
rna
helminth infections
eukaryota
rna processing
brugia malayi
cell biology
anatomy
nucleic acids
genetics
nematoda
biology and life sciences
cellular types
frogs
organisms
Emodepside has sex-dependent immobilizing effects on adult Brugia malayi due to a differentially spliced binding pocket in the RCK1 region of the SLO-1 K channel